Hapalindole Q (Compound (+)-1) is an autophagy ( Autophagy ) inhibitor targeting YAP1. Hapalindole Q binds to the Hippo pathway transcription factor YAP1 with a K d of 9.13 μM and induces its degradation via the chaperone-mediated autophagy (CMA) pathway. This process inhibits Rab7 -mediated fusion of autophagosomes and lysosomes, thereby reducing overall autophagy levels without affecting lysosomal function. Hapalindole Q holds promise for research in cancer (e.g., liver cancer, breast cancer, etc.) [1].
References:
[1]. Wu Y, et al. Hapalindole Q suppresses autophagosome-lysosome fusion by promoting YAP1 degradation via chaperon-mediated autophagy. Proc Natl Acad Sci U S A. 2024 Dec 10;121(50):e2400809121.
References:
[1]. Wu Y, et al. Hapalindole Q suppresses autophagosome-lysosome fusion by promoting YAP1 degradation via chaperon-mediated autophagy. Proc Natl Acad Sci U S A. 2024 Dec 10;121(50):e2400809121.